AJR 19: Opioid awareness and dependency prevention: patient-centered postsurgical care.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2017-09-25
This measure, the California Access to Patient-Centered Postsurgical Care Resolution, would urge the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
This measure, the California Access to Patient-Centered Postsurgical Care Resolution, would urge the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
This measure, the California Access to Patient-Centered Postsurgical Care Resolution, would urge public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency and would urge the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
This measure, the California Opioid Awareness and Dependency Prevention Access to Patient-Centered Postsurgical Care Resolution, would urge public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency and would urge the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
This measure, the California Opioid Awareness and Dependency Prevention Resolution, would urge public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency and would urge the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
WHEREAS, The National Academy of Medicine notes an increase in pain prevalence and assumes an increase in chronic pain, due in part to the risks associated with undermanaged acute postsurgical pain that may evolve into chronic pain; and
WHEREAS, Most chronic pain problems begin with an acute nociceptive pain episode. In these instances, pain is usually a symptomatic reflection of an underlying disorder or injury. Prompt, effective, and appropriate management is essential, however, when acute pain does not resolve, as it may be associated with a serious disease, condition, or injury that may evolve into chronic pain; and
WHEREAS, Current pharmaceutical-based treatments for pain commonly rely on two classes of drugs: opioids and nonsteroidal anti-inflammatory drugs. Both have side effects and risk of serious complications; and
WHEREAS, Opioid misuse is a national epidemic in the United States, according to the federal Centers for Disease Control and Prevention; and
WHEREAS, According to the Journal of Pain & Palliative Care Pharmacotherapy, 95 percent of postsurgical patients receive an opioid; and
WHEREAS, In April 2017, the Annals of Surgery journal noted that after common surgical procedures, a recent study found only 28.7 percent of the pills that were prescribed were taken; 90 percent of patients had received opioid pills with prescribed amounts up to 120 pills; in dental procedures, 54 percent of patients had leftover pills after surgical tooth extraction, and there were an estimated 100 million unused medications after those extractions, as stated by the Drug and Alcohol Dependence journal; and
WHEREAS, According to a Substance Abuse and Mental Health Services Administration survey, approximately 70 percent of people who misuse opioids report obtaining them from family, friends, or on the street, stressing the need to address unused opioids; and
WHEREAS, Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain; and
WHEREAS, The National Pain Strategy, released by the United States Department of Health and Human Services in 2016, made recommendations for improving overall pain care in the United States, including supporting the development of a system of patient-centered integrated pain management practices based on a biopsychosocial model of care that enables providers and patients to access the full spectrum of pain treatment options, such as comprehensive, multimodal pain management approaches; and
WHEREAS, The Joint Commission recommends an individualized, multimodal treatment plan should be used to manage pain and the best approach may be to start with a nonnarcotic; and
WHEREAS, The federal Centers for Disease Control and Prevention recommends that health care providers should only use opioids in carefully screened and monitored patients when nonopioid treatments are insufficient to manage pain; and
WHEREAS, The American Society of Anesthesiologists recommends a multimodal approach to pain management, often beginning with a local anesthetic where appropriate; and
WHEREAS, The National Pain Strategy envisions an environment where payment structures would encourage comprehensive, multimodal pain management care; and
WHEREAS, The National Academy of Medicine recommends that reimbursement policies be revised to foster coordinated and evidence-based pain care with optimal care of the patient as the focus; and
WHEREAS, The National Pain Strategy outlined steps to reduce barriers to pain care and improve the quality of pain care by increasing patient knowledge of treatment options and risks, and helping to develop a better informed health care workforce with regard to pain management, including risks of drug dependence and addiction; now, therefore, be it
Resolved by the Assembly and the Senate of the State of California, jointly, That the Legislature urges hospital-based pain management formularies to consider the inclusion of a range of nonopioid alternatives; and be it further
Resolved, That the Legislature urges the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain; and be it further
Resolved, That this measure shall be known as the California Access to Patient-Centered Postsurgical Care Resolution; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Minority Leader of the House of Representatives, to the Majority Leader of the Senate, to the Minority Leader of the Senate, and to each Senator and Representative from California in the Congress of the United States.
WHEREAS, The National Academy of Medicine notes an increase in pain prevalence and assumes an increase in chronic pain, due in part to the risks associated with undermanaged acute postsurgical pain that may evolve into chronic pain; and
WHEREAS, Most chronic pain problems begin with an acute nociceptive pain episode. In these instances, pain is usually a symptomatic reflection of an underlying disorder or injury. Prompt, effective, and appropriate management is essential, however, when acute pain does not resolve, as it may be associated with a serious disease, condition, or injury that may evolve into chronic pain; and
WHEREAS, Current pharmaceutical-based treatments for pain commonly rely on two classes of drugs: opioids and nonsteroidal anti-inflammatory drugs. Both have side effects and risk of serious complications; and
WHEREAS, Opioid misuse is a national epidemic in the United States, according to the federal Centers for Disease Control and Prevention; and
WHEREAS, According to the Journal of Pain & Palliative Care Pharmacotherapy, 95 percent of postsurgical patients receive an opioid; and
WHEREAS, In April 2017, the Annals of Surgery journal noted that after common surgical procedures, a recent study found only 28.7 percent of the pills that were prescribed were taken; 90 percent of patients had received opioid pills with prescribed amounts up to 120 pills; in dental procedures, 54 percent of patients had leftover pills after surgical tooth extraction, and there were an estimated 100 million unused medications after those extractions, as stated by the Drug and Alcohol Dependence journal; and
WHEREAS, According to a Substance Abuse and Mental Health Services Administration survey, approximately 70 percent of people who misuse opioids report obtaining them from family, friends, or on the street, stressing the need to address unused opioids; and
WHEREAS, Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain; and
WHEREAS, The National Pain Strategy, released by the United States Department of Health and Human Services in 2016, made recommendations for improving overall pain care in the United States, including supporting the development of a system of patient-centered integrated pain management practices based on a biopsychosocial model of care that enables providers and patients to access the full spectrum of pain treatment options, such as comprehensive, multimodal pain management approaches; and
WHEREAS, The Joint Commission recommends an individualized, multimodal treatment plan should be used to manage pain and the best approach may be to start with a nonnarcotic; and
WHEREAS, The federal Centers for Disease Control and Prevention recommends that health care providers should only use opioids in carefully screened and monitored patients when nonopioid treatments are insufficient to manage pain; and
WHEREAS, The American Society of Anesthesiologists recommends a multimodal approach to pain management, often beginning with a local anesthetic where appropriate; and
WHEREAS, The National Pain Strategy envisions an environment where payment structures would encourage comprehensive, multimodal pain management care; and
WHEREAS, The National Academy of Medicine recommends that reimbursement policies be revised to foster coordinated and evidence-based pain care with optimal care of the patient as the focus; and
WHEREAS, The National Pain Strategy outlined steps to reduce barriers to pain care and improve the quality of pain care by increasing patient knowledge of treatment options and risks, and helping to develop a better informed health care workforce with regard to pain management, including risks of drug dependence and addiction; now, therefore, be it
Resolved by the Assembly and the Senate of the State of California, jointly, That the Legislature urges hospital-based pain management formularies to consider the inclusion of a range of nonopioid alternatives; and be it further
Resolved, That the Legislature urges the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain; and be it further
Resolved, That this measure shall be known as the California Access to Patient-Centered Postsurgical Care Resolution; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Minority Leader of the House of Representatives, to the Majority Leader of the Senate, to the Minority Leader of the Senate, and to each Senator and Representative from California in the Congress of the United States.
WHEREAS, The National Academy of Medicine notes an increase in pain prevalence and assumes an increase in chronic pain, due in part to the risks associated with undermanaged acute postsurgical pain that may evolve into chronic pain; and
WHEREAS, Most chronic pain problems begin with an acute nociceptive pain episode. In these instances, pain is usually a symptomatic reflection of an underlying disorder or injury. Prompt, effective, and appropriate management is essential, however, when acute pain does not resolve, as it may be associated with a serious disease, condition, or injury that may evolve into chronic pain; and
WHEREAS, Current pharmaceutical-based treatments for pain commonly rely on two classes of drugs: opioids and nonsteroidal anti-inflammatory drugs. Both have side effects and risk of serious complications; and
WHEREAS, Opioid misuse is a national epidemic in the United States, according to the federal Centers for Disease Control and Prevention; and
WHEREAS, According to the Journal of Pain & Palliative Care Pharmacotherapy, 95 percent of postsurgical patients receive an opioid; and
WHEREAS, In April 2017, the Annals of Surgery journal noted that after common surgical procedures, a recent study found only 28.7 percent of the pills that were prescribed were taken; 90 percent of patients had received opioid pills with prescribed amounts up to 120 pills; and in dental procedures, 54 percent of patients had leftover pills after surgical tooth extraction, and there are after such extractions were an estimated 100 million unused medications after those extractions, as stated by the Drug and Alcohol Dependence journal; and
WHEREAS, According to a Substance Abuse and Mental Health Services Administration survey, approximately 70 percent of people who misuse opioids report obtaining them from family, friends, or on the street, stressing the need to address unused opioids; and
WHEREAS, Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain; and
WHEREAS, The National Pain Strategy, released by the United States Department of Health and Human Services in 2016, made recommendations for improving overall pain care in the United States, including supporting the development of a system of patient-centered integrated pain management practices based on a biopsychosocial model of care that enables providers and patients to access the full spectrum of pain treatment options, such as comprehensive, multimodal pain management approaches; and
WHEREAS, The Joint Commission recommends an individualized, multimodal treatment plan should be used to manage pain and the best approach may be to start with a nonnarcotic; and
WHEREAS, The federal Centers for Disease Control and Prevention recommends that health care providers should only use opioids in carefully screened and monitored patients when nonopioid treatments are insufficient to manage pain; and
WHEREAS, The American Society of Anesthesiologists recommends a multimodal approach to pain management, often beginning with a local anesthetic where appropriate; and
WHEREAS, The National Pain Strategy envisions an environment where payment structures would encourage comprehensive, multimodal pain management care, and
WHEREAS, The National Academy of Medicine recommends that reimbursement policies be revised to foster coordinated and evidence-based pain care with optimal care of the patient as the focus; and
WHEREAS, The National Pain Strategy outlined steps to reduce barriers to pain care and improve the quality of pain care by increasing patient knowledge of treatment options and risks, and helping to develop a better informed health care workforce with regard to pain management, including risks of drug dependence and addiction; now, therefore, be it
Resolved by the Assembly and the Senate of the State of California, jointly, That the Legislature urges hospital-based pain management formularies to consider the inclusion of a range of nonopioid alternatives; and be it further
Resolved, That the Legislature urges public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency; and be it furtherResolved, That the Legislature urges the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain; and be it further
Resolved, That this measure shall be known as the California Access to Patient-Centered Postsurgical Care Resolution; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Minority Leader of the House of Representatives, to the Majority Leader of the Senate, to the Minority Leader of the Senate, and to each Senator and Representative from California in the Congress of the United States.
WHEREAS, The National Academy of Medicine notes an increase in pain prevalence and assumes an increase in chronic pain, due in part to the risks associated with undermanaged acute postsurgical pain that may evolve into chronic pain; and
WHEREAS, Most chronic pain problems begin with an acute nociceptive pain episode. In these instances, pain is usually a symptomatic reflection of an underlying disorder or injury. Prompt, effective, and appropriate management is essential, however, when acute pain does not resolve, as it may be associated with a serious disease, condition, or injury that may evolve into chronic pain; and
WHEREAS, Current pharmaceutical-based treatments for pain commonly rely on two classes of drugs: opioids and nonsteroidal anti-inflammatory drugs. Both have side effects and risk of serious complications; and
WHEREAS, Opioid misuse is a national epidemic in the United States, according to the federal Centers for Disease Control and Prevention; and
WHEREAS, According to the Journal of Pain & Palliative Care Pharmacotherapy, 95 percent of postsurgical patients receive an opioid, expanding the effects of opioid dependency on socioeconomic stress and the overall cost of treatment and care; and opioid; and
WHEREAS, Peer-reviewed survey results in Anesthesia & Analgesia and JAMA Internal Medicine state that one in 15 surgical patients becomes a chronic opioid user after his or her procedure, and each day, 46 people in the United States die from an overdose of prescription pain killers; andWHEREAS, According to Hospital Pharmacy, with over 70 million surgical procedures performed annually in the United States, if one in 15 surgical patients becomes dependent on opioids after surgery, then approximately four million people annually will need care. Strategies for helping patients achieve pain relief and minimize use of opioids such as Vicodin, OxyContin and Percocet are needed now more than ever; andWHEREAS, In 2013, there were 230 million prescriptions for opioids, according to data from IMS Health; andWHEREAS, In March 2016, April 2017, the Annals of Surgery journal noted that after common surgical procedures, a recent study found only 28.7 percent of the pills that were prescribed were taken; 90 percent of patients had received opioid pills with a range of zero prescribed amounts up to 120 pills; and in dental procedures, 54 percent of patients had leftover pills after surgical tooth extraction extraction, and there are after such extractions an estimated 100 million unused medications as stated by the Drug and Alcohol Dependence; Dependence journal; and
WHEREAS, According to a study published by the Oxford University Press in 2014, dependency on these opioid medications has risen sharply, with patients given opioids within seven days of discharge being almost 50 percent more likely to still be on them one year after surgery and opioid-related adverse drug events being the most common postdischarge complication; andWHEREAS, As acknowledged in a recent FAIR Health, Inc. white paper entitled The Impact of the Opioid Crisis on the Healthcare System, health insurers spent $446 million on opioid treatment in 2015, and health insurers have seen their payments to hospitals, laboratories, treatment centers, and other providers skyrocket 1,375 percent from 2011 to 2015 for patients diagnosed with an opioid dependence or opioid abuse disorder, and health insurers also saw treatment costs rise from $32 million to $446 million over the same period, with the average yearly cost per patient rising from $3,435 to over $19,000 to battle opioid dependence; andWHEREAS, The cost of opioid misuse and abuse has risen from $55.7 billion in 2007 to $78.5 billion in 2013 as reported by Medical Care in 2016; andWHEREAS, According to a Substance Abuse and Mental Health Services Administration survey, approximately 70 percent of people who misuse opioids report obtaining them from family, friends, or on the street, stressing the need to address unused opioids; and
WHEREAS, Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain; and
WHEREAS, The National Pain Strategy, released by the United States Department of Health and Human Services in 2016, made recommendations for improving overall pain care in the United States, including supporting the development of a system of patient-centered integrated pain management practices based on a biopsychosocial model of care that enables providers and patients to access the full spectrum of pain treatment options, such as comprehensive, multimodal pain management approaches; and
WHEREAS, The Joint Commission recommends an individualized, multimodal treatment plan should be used to manage pain upon assessment, and the best approach may be to start with a nonnarcotic; and
WHEREAS, The United States federal Centers for Disease Control and Prevention recommends that health care providers should only use opioids in carefully screened and monitored patients when nonopioid treatments are insufficient to manage pain; and
WHEREAS, The American Society of Anesthesiologists recommends a multimodal approach to pain management, often beginning with a local anesthetic where appropriate; and
WHEREAS, Patients undergoing a surgical intervention deserve to be educated that the use of opioids can lead to dependency and that all patients deserve to have open, unrestricted access to nonopioid alternative medications for their postsurgical pain; now, therefore, be itResolved by the Assembly and the Senate of the State of California, jointly, That the Legislature urges inclusion of medications like liposomals, bupivacaine, intravenous acetaminophen and other nonopioid alternatives to hospital-based pain management formularies; and be it furtherWHEREAS, The National Pain Strategy envisions an environment where payment structures would encourage comprehensive, multimodal pain management care, and
WHEREAS, The National Academy of Medicine recommends that reimbursement policies be revised to foster coordinated and evidence-based pain care with optimal care of the patient as the focus; and
WHEREAS, The National Pain Strategy outlined steps to reduce barriers to pain care and improve the quality of pain care by increasing patient knowledge of treatment options and risks, and helping to develop a better informed health care workforce with regard to pain management, including risks of drug dependence and addiction; now, therefore, be it
RESOLVED BY THE ASSEMBLY AND THE SENATE OF THE STATE OF CALIFORNIA, JOINTLY, That the Legislature urges hospital-based pain management formularies to consider the inclusion of a range of nonopioid alternatives; and be it further
Resolved, That the Legislature urges public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency; and be it further
Resolved, That the Legislature urges the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain; and be it further
Resolved, That this measure shall be known as the California Opioid Awareness and Dependency Prevention Access to Patient-Centered Postsurgical Care Resolution; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Minority Leader of the House of Representatives, to the Majority Leader of the Senate, to the Minority Leader of the Senate, and to each Senator and Representative from California in the Congress of the United States.
WHEREAS, Opioid dependency has become a health care epidemic in California and the United States of America; and
WHEREAS, According to the Journal of Pain & Palliative Care Pharmacotherapy, 95 percent of postsurgical patients receive an opioid, expanding the effects of opioid dependency on socioeconomic stress and the overall cost of treatment and care; and
WHEREAS, Peer-reviewed survey results in Anesthesia & Analgesia and JAMA Internal Medicine state that one in 15 surgical patients becomes a chronic opioid user after his or her procedure, and each day, 46 people in the United States die from an overdose of prescription pain killers; and
WHEREAS, According to Hospital Pharmacy, with over 70 million surgical procedures performed annually in the United States, if one in 15 surgical patients becomes dependent on opioids after surgery, then approximately four million people annually will need care. Strategies for helping patients achieve pain relief and minimize use of opioids such as Vicodin, OxyContin and Percocet are needed now more than ever; and
WHEREAS, In 2013, there were 230 million prescriptions for opioids, according to data from IMS Health; and
WHEREAS, In March 2016, Annals of Surgery noted that after common surgical procedures, a recent study found only 28.7 percent of the pills that were prescribed were taken; 90 percent of patients had received opioid pills with a range of zero to 120 pills; and in dental procedures, 54 percent of patients had leftover pills after surgical tooth extraction and there are after such extractions an estimated 100 million unused medications as stated by Drug and Alcohol Dependence; and
WHEREAS, According to a study published by the Oxford University Press in 2014, dependency on these opioid medications has risen sharply, with patients given opioids within seven days of discharge being almost 50 percent more likely to still be on them one year after surgery and opioid-related adverse drug events being the most common postdischarge complication; and
WHEREAS, As acknowledged in a recent FAIR Health, Inc. white paper entitled The Impact of the Opioid Crisis on the Healthcare System, health insurers spent $446 million on opioid treatment in 2015, and health insurers have seen their payments to hospitals, laboratories, treatment centers, and other providers skyrocket 1,375 percent from 2011 to 2015 for patients diagnosed with an opioid dependence or opioid abuse disorder, and health insurers also saw treatment costs rise from $32 million to $446 million over the same period, with the average yearly cost per patient rising from $3,435 to over $19,000 to battle opioid dependence; and
WHEREAS, The cost of opioid misuse and abuse has risen from $55.7 billion in 2007 to $78.5 billion in 2013 as reported by Medical Care in 2016; and
WHEREAS, Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain; and
WHEREAS, The Joint Commission recommends an individualized, multimodal treatment plan should be used to manage pain upon assessment, the best approach may be to start with a nonnarcotic; and
WHEREAS, The United States Centers for Disease Control and Prevention recommends that health care providers should only use opioids in carefully screened and monitored patients when nonopioid treatments are insufficient to manage pain; and
WHEREAS, The American Society of Anesthesiologists recommends a multimodal approach to pain management, often beginning with a local anesthetic where appropriate; and
WHEREAS, Patients undergoing a surgical intervention deserve to be educated that the use of opioids can lead to dependency and that all patients deserve to have open, unrestricted access to nonopioid alternative medications for their postsurgical pain; now, therefore, be it
Resolved by the Assembly and the Senate of the State of California, jointly, That the Legislature urges inclusion of medications like liposomals, bupivacaine, intravenous acetaminophen and other nonopioid alternatives to hospital-based pain management formularies; and be it further
Resolved, That the Legislature urges public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency; and be it further
Resolved, That the Legislature urges the President of the United States and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain; and be it further
Resolved, That this measure shall be known as the California Opioid Awareness and Dependency Prevention Resolution; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Minority Leader of the House of Representatives, to the Majority Leader of the Senate, to the Minority Leader of the Senate, and to each Senator and Representative from California in the Congress of the United States.
|
Date
|
Status
|
|---|---|
| Sep 25, 2017 | Chaptered by Secretary of State - Res. Chapter 208, Statutes of 2017. |
| Sep 25, 2017 | Enrolled and filed with the Secretary of State at 3 p.m. |
| Sep 14, 2017 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Sep 13, 2017 | In Assembly. Concurrence in Senate amendments pending. |
| Sep 12, 2017 | Adopted and to Assembly. |
| Sep 6, 2017 | From committee: Ordered to third reading. |
| Sep 5, 2017 | From committee chair, with author's amendments: Amend, and re-refer to committee. Amended and re-referred to Com. on RLS. |
| Aug 24, 2017 | In Senate. To Com. on RLS. |
| Aug 24, 2017 | Adopted and to Senate. |
| Aug 21, 2017 | Amended. Ordered to Consent Calendar. |
| Jul 20, 2017 | From committee: Amend, and be adopted as amended. To Consent Calendar. (Ayes 15. Noes 0.) (July 11). |
| Jun 12, 2017 | Referred to Com. on HEALTH. |
| Jun 6, 2017 | From printer. |
| Jun 5, 2017 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 14, 2017 | AJR 19 ARAMBULA Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 12, 2017 | Assembly 3rd Reading AJR19 Arambula By Leyva | Senate Floor |
Passed |
|
| Aug 24, 2017 | AJR 19 ARAMBULA Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Jul 11, 2017 | Be adopted as amended. To Consent Calendar. | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| California State Association Of Counties | ** Support | Sep 6, 2017 |
| pacira pharmaceuticals | ** Support | Sep 6, 2017 |
| Pharmaceutical Research And Manufacturers Of America | ** Support | Sep 6, 2017 |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AJR 19
Author:(Arambula)
As Amended Ver:September 5, 2017
Majority vote
ASSEMBLY: | 76-0 | (August 24, 2017) | SENATE: | 39-0 | (September 12, 2017) |
Original Committee Reference: HEALTH
SUMMARY: Resolves that the Legislature urges the use of non-opioid alternatives for pain management and supports physician choice of treatment to prevent opioid dependency. Specifically, this resolution:
- Resolves that the Legislature urge the following:
- The inclusion of medications like liposomals, bupivacaine, intravenous acetaminophen, and other non-opioid alternatives to hospital-based pain management formularies;
- Public and private health care payers, state and federal regulators, agencies, and departments, the President and Congress to support physician choice of treatment to prevent opioid dependency; and,
- The President and Congress to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
- States that this resolution will be known as the California Opioid Awareness and Dependency Prevention Resolution.
- Makes various findings and declarations regarding the opioid crisis in California and the United States.
The Senate amendments delete a resolve that states "the Legislature urges public and private health care payers, state and federal regulators, agencies, and departments, the President of the United States, and the Congress of the United States to support physician and surgeon choice of treatment to prevent opioid dependency" and make other minor technical changes.
FISCAL EFFECT: None
COMMENTS: According to the author, opioid addiction and overdosing is a multi-faceted issue that is growing in the United States and in California specifically. The author reports that a 2014 study that showed the danger of post-operative use of opioids, specifically those patients given opioids within seven days of hospital discharge were almost 50% more likely to still be on them one year after surgery and that opioid-related adverse drug events are the most common post-discharge complication. With over 2,000 opioid overdose deaths in California in 2014 alone, there are steps that the Legislature can take to prevent the over prescription of opioids and minimize the number of pills available for unintentional or intentional diversion. The author believes that California legislators need to urge the federal administration to work towards ending opioid dependency by supporting multimodal therapy guidelines for managing postsurgical acute pain.
Analysis Prepared by: John Gilman / HEALTH / (916) 319-2097 FN: 0002070
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AJR 19 |
THIRD READING
Bill No: AJR 19
Amended: 9/5/17 in Senate
ASSEMBLY FLOOR: 76-0, 8/24/17 (Consent) - See last page for vote
SUBJECT: Opioid awareness and dependency prevention: patient-centered postsurgical care
SOURCE: Pacira Pharmaceuticals
DIGEST:
This resolution, the California Access to Patient-Centered Postsurgical Care Resolution, urges the President and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
ANALYSIS: This resolution makes the following legislative findings:
- The National Academy of Medicine notes an increase in pain prevalence and assumes an increase in chronic pain, due in part to the risks associated with undermanaged acute postsurgical pain that may evolve into chronic pain.
- Current pharmaceutical-based treatments for pain commonly rely on two classes of drugs: opioids and nonsteroidal anti-inflammatory drugs. According to the Journal of Pain & Palliative Care Pharmacotherapy, 95% of postsurgical patients receive an opioid.
- Opioid misuse is a national epidemic in the U.S., according to the federal Centers for Disease Control and Prevention.
- Multimodal pain control is the use of different medications that control pain at different receptor sites in the body, beginning with local anesthetics, and this strategy reserves the use of opioid medications for breakthrough pain.
- The National Pain Strategy, released by the U.S. Department of Health & Human Services in 2016, made recommendations for improving overall pain care in the U.S., including supporting the development of a system of patient-centered integrated pain management practices based on a biopsychosocial model of care that enables providers and patients to access the full spectrum of pain treatment options. The Strategy outlined steps to reduce barriers to pain care and improve the quality of pain care by increasing patient knowledge of treatment options and risks, and helping to develop a better informed health care workforce with regard to pain management, including risks of drug dependence and addiction.
This resolution, the California Access to Patient-Centered Postsurgical Care Resolution, urges hospital-based pain management formularies to consider the inclusion of a range of nonopioid alternatives; and urges the President and the Congress of the United States to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
Pacira Pharmaceuticals (source)
AFSCME
California State Association of Counties
Pharmaceutical Research and Manufacturers of America
None received
ASSEMBLY FLOOR: 76-0, 8/24/17
AYES: Acosta, Arambula, Baker, Berman, Bigelow, Bloom, Bocanegra, Bonta, Brough, Burke, Caballero, Calderon, Cervantes, Chau, Chávez, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dababneh, Dahle, Daly, Eggman, Flora, Fong, Frazier, Friedman, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez Fletcher, Gray, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Quirk-Silva, Reyes, Ridley-Thomas, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Aguiar-Curry, Travis Allen, McCarty
Prepared by: Melissa Ward / SFA / (916) 651-1520
9/6/17 16:23:12
Date of Hearing: July 11, 2017
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AJR 19 (
Author:Arambula) – As Introduced Ver:June 5, 2017
SUBJECT: Opioid awareness and dependency prevention.
SUMMARY: Resolves that the Legislature urges the use of non-opioid alternatives for pain management and supports physician choice of treatment to prevent opioid dependency. Specifically, this resolution:
- Resolves that the Legislature urge the following:
- The inclusion of medications like liposomals, bupivacaine, intravenous acetaminophen, and other non-opioid alternatives to hospital-based pain management formularies;
- Public and private health care payers, state and federal regulators, agencies, and departments, the President and Congress to support physician choice of treatment to prevent opioid dependency; and,
- The President and Congress to move forward with legislation to establish multimodal therapy guidelines for managing postsurgical acute pain.
- The inclusion of medications like liposomals, bupivacaine, intravenous acetaminophen, and other non-opioid alternatives to hospital-based pain management formularies;
- States that this resolution will be known as the California Opioid Awareness and Dependency Prevention Resolution.
- Makes various findings and declarations regarding the opioid crisis in California and the United States.
EXISTING LAW:
- Establishes the Uniform Controlled Substances Act which regulates controlled substances and defines opiate as any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability.
- Classifies controlled substances in five schedules according to their danger and potential for abuse. Requires special prescription forms for controlled substances and requires each prescription for a controlled substance classified in Schedule II, III, IV or IV to be made on the specified form.
- Establishes, within the Department of Consumer Affairs, various Boards charged with regulating medical professionals, including the Board of Pharmacy and the Medical Board of California (MBC), which oversee pharmacists and physicians and surgeons, respectively.
- Authorizes various health professionals to issue prescriptions for controlled substances.
- Provides that a physician and surgeon may not prescribe, dispense, or administer dangerous drugs or controlled substances to a person he or she knows or reasonably believes is using or will use the drugs or substances for a nonmedical purpose. Authorizes MBC to take any action against a physician and surgeon for inappropriate prescribing.
- Authorizes the MBC to consult with specified entities in developing the standards utilizing current authoritative clinical practice guidelines on pain control therapies.
FISCAL EFFECT: None
COMMENTS:
- PURPOSE OF THIS RESOLUTION. According to the author, opioid addiction and overdosing is a multi-faceted issue that is growing in the United States and in California specifically. The author reports that a 2014 study that showed the danger of post-operative use of opioids, specifically that patients given opioids within seven days of hospital discharge were almost 50% more likely to still be on them one year after surgery and that opioid-related adverse drug events are the most common post-discharge complication. With over 2,000 opioid overdose deaths in California in 2014 alone, there are steps that the Legislature can take to prevent the over prescription of opioids and minimize the number of pills available for unintentional or intentional diversion. The author believes that California legislators need to urge the federal administration to work towards ending opioid dependency by supporting physician and surgeon research and choice of treatment.
- BACKGROUND.
- Opioid Abuse. According to the Department of Public Health (DPH) in the past, prescription opioids were prescribed for relieving short-term (acute) pain. Today, they are increasingly being used for long-term (chronic) pain management. As a result, sales of opioid pain relievers quadrupled in the past 10 years. By 2010, enough opioid pain relievers were sold in the U.S. to medicate every American adult every four hours for an entire month. Drug overdose is now the leading cause of accidental death, exceeding deaths due to motor vehicle accidents. In California, deaths involving opioid prescription medications have increased 21% since 2006. In 2013, there were more than 1,400 deaths from prescription opioids. In 2014, over 9,000 emergency department (ED) visits were related to prescription opioids, more than double the number in 2006. The highest rates of death and ED visits are found in several northern California rural counties. For example, Plumas and Lake Counties have age adjusted death rates more than seven times the state average.
According to a July 6, 2017 article in the Journal of the American Medical Association, the national opioid overdose epidemic mirrors that in the state. In 2015, opioid-involved drug overdoses nationally accounted for 33,091 deaths, approximately half involving prescription opioids. Additionally, an estimated 2 million individuals in the United States have opioid use disorder (addiction) associated with prescription opioids, accounting for an estimated $78.5 billion in economic costs annually. Although the amount of opioids prescribed in the United States peaked in 2010, the amount prescribed in 2015 is more than three times higher than in 1999 and nearly four times higher than in Europe in 2015.
According to information provided by the federal Drug Enforcement Agency (DEA), a 2014 national survey found an estimated 1.4 million people in the U.S. abused a prescription painkiller for the first time that year; most first-time abusers of painkillers obtain them from a friend or relative; in the 1960s, more than 80% of opioid abusers got hooked on heroin first, but in the 2000s, 75% of opioid abusers started with a prescription; more than 10 million people 12 years and older in the U.S. reported nonmedical use of prescription opioids in 2014; and, each day, 44 people in the U.S. die from an overdose of prescription painkillers. - Opioids. Opioids are a class of narcotic drugs that include medications such as hydrocodone, oxycodone, morphine, codeine, and other related drugs that are derived from compounds found in the opium poppy plant, or synthetic drugs that contain substances that mimic these compounds. Taken as prescribed, opioids can be used to manage pain safely and effectively. However, opioids may also produce other effects, and according to the National Institute on Drug Abuse (NIDA), some individuals experience a euphoric response to opioid medications since these drugs affect the regions of the brain involving reward response. NIDA states that those who abuse opioids may seek to intensify their experience by taking the drug in ways other than those prescribed. NIDA states that when abused, even a single large dose of opioids can cause severe respiratory depression and death.
In June 2016, the U.S. Senate Judiciary Committee held a hearing with the acting administrator for the DEA on opioid abuse. According to information provided at this hearing, in 2014 alone, the industry put 14 billion opioid pills on the market with DEA approval. The DEA sets annual production quotas for opioids, between 1993 and 2015, oxycodone production jumped from 3.5 tons to 150 tons. During that same period, the production of hydrocodone increased 12-fold, hydromorphone 23-fold, and fentanyl 25-fold. - Controlled Substances Act. Certain drugs are classified under the federal Controlled Substances Act of 1970 (CSA) into one of five schedules. Placement in a given schedule depends on whether a drug has a currently accepted medical use, its relative abuse potential, and its likelihood of causing either addiction or physical dependency when abused. Most opioid analgesics are schedule II drugs, in that they have a recognized medical use, but also have a high potential for abuse that may lead to severe psychological dependence or severe physical dependence. The CSA places a number of restrictions on prescribers and pharmacies that dispense controlled substances like opioids. For example, refills are not permitted and a new written prescription must be presented each time the drug is dispensed.
- Opioid Abuse. According to the Department of Public Health (DPH) in the past, prescription opioids were prescribed for relieving short-term (acute) pain. Today, they are increasingly being used for long-term (chronic) pain management. As a result, sales of opioid pain relievers quadrupled in the past 10 years. By 2010, enough opioid pain relievers were sold in the U.S. to medicate every American adult every four hours for an entire month. Drug overdose is now the leading cause of accidental death, exceeding deaths due to motor vehicle accidents. In California, deaths involving opioid prescription medications have increased 21% since 2006. In 2013, there were more than 1,400 deaths from prescription opioids. In 2014, over 9,000 emergency department (ED) visits were related to prescription opioids, more than double the number in 2006. The highest rates of death and ED visits are found in several northern California rural counties. For example, Plumas and Lake Counties have age adjusted death rates more than seven times the state average.
- SUPPORT. Pacira Pharmaceuticals, the maker of bupivacaine liposome, a long-acting non-opioid local analgesic and the sponsor of this resolution, argues that patients undergoing a surgical intervention deserve to be educated that the use of opioids can lead to dependency and that all patients deserve to have open, unrestricted access to non-opioid alternative medications for their postsurgical pain.
- RELATED LEGISLATION.
- AB 715 (Wood) requires DPH to convene a workgroup for the purpose of reviewing existing guidelines and developing a recommended statewide guideline regarding the prescribing of opioid pain relievers for instances of acute, short-term pain. Requires DPH to report to the Legislature on or before March 1, 2019. Sunsets these provisions on January 1, 2020. AB 715 is pending in the Senate Appropriations Committee.
- AB 1048 (Arambula) authorizes a partial fill on a Schedule II drug prescription, and deletes the requirement that hospitals assess pain at the time of checking vital signs. AB 1048 is pending in the Senate Health Committee.
- AB 1512 (McCarty) would have imposed a tax of one cent ($0.01) per milligram on the distribution of opioids and required the amounts collected to be used for addiction prevention and rehabilitation programs. AB 1512 was held in the Assembly Revenue and Taxation Committee.
- AB 182 (Waldron) requires DPH to develop, coordinate, implement, and oversee a public awareness campaign, as specified, upon appropriation or receipt of adequate state or federal funds, to educate targeted audiences about the growing heroin use and opioid medication abuse epidemic, as well as the importance and availability of services to avert addiction and to treat substance use disorders. AB 182 is pending in the Senate Appropriations Committee.
- SB 419 (Portantino) would have set forth requirements for controlled substances prescriptions for minors and required MBC to convene a task force to update standards of review regarding pain management. SB 419 failed passage in the Senate Business, Professions and Economic Development Committee.
- AB 715 (Wood) requires DPH to convene a workgroup for the purpose of reviewing existing guidelines and developing a recommended statewide guideline regarding the prescribing of opioid pain relievers for instances of acute, short-term pain. Requires DPH to report to the Legislature on or before March 1, 2019. Sunsets these provisions on January 1, 2020. AB 715 is pending in the Senate Appropriations Committee.
- PREVIOUS LEGISLATION.
- AB 1977 (Wood) of 2016 would have established the Opioid Abuse Task Force to develop recommendations to the Legislature regarding the abuse and misuse of opioids in California. AB 1977 was later amended in the Senate to address a different topic.
- AB 623 (Wood) of 2015 would have prohibited health care service plans or health insurers from requiring the use of opioids that have no abuse-deterrent properties; required pharmacists to provide patients receiving an opioid product information about proper storage and disposal; and, authorized providers to prescribe less than 30-day supplies of opioids. AB 623 was held in the Assembly Appropriations Committee.
- AB 831 (Bloom) of 2013 would have required the California Health and Human Services Agency (CHHSA) to convene a temporary working group to develop a state plan to reduce the rate of fatal drug overdoses and would have appropriated $500,000 from the General Fund to CHHSA to provide grants to local agencies to implement drug overdose prevention and response programs. AB 831 was held in the Assembly Appropriations Committee.
- AB 1977 (Wood) of 2016 would have established the Opioid Abuse Task Force to develop recommendations to the Legislature regarding the abuse and misuse of opioids in California. AB 1977 was later amended in the Senate to address a different topic.
- AMENDMENT. On page 3, lines 16-25, the Committee requests the following substantive amendments:
WHEREAS, Patients undergoing a surgical intervention deserve
to be educated that the use of opioids can lead to dependency and
that all patients deserve to have open, unrestricted access to
nonopioid alternative medications for their postsurgical pain are available ; now,
therefore, be it
Resolved by the Assembly and the Senate of the State of
California, jointly, That the Legislature urges that hospital-based pain management formularies consider the inclusion of a range of nonopioid alternatives; inclusion of
medications like liposomals, bupivacaine, intravenous
acetaminophen and other nonopioid alternatives to hospital-based
pain management formularies; and be it further
- TECHNICAL AMENDMENTS. The Committee recommends the following technical amendments:
- On page 1, line 8, before “Anesthesia” insert “the journals”
- On page 2, line 4, before “Hospital” insert “the journal”
- On page 2, line 19, before “Drug” insert “the journal”
- On page 2, line 40, before “Medical” insert “the journal”
- On page 3, line 7, delete “—upon assessment,” and replace with “and”
REGISTERED SUPPORT / OPPOSITION:
Support
Pacira Pharmaceuticals (sponsor)
American Federation of State, County and Municipal Employees, AFL-CIO
California State Association of Counties
Opposition
None on file.
Analysis Prepared by: John Gilman / HEALTH / (916) 319-2097
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):